459 related articles for article (PubMed ID: 18430202)
21. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.
Walsby E; Pearce L; Burnett AK; Fegan C; Pepper C
Oncotarget; 2012 May; 3(5):525-34. PubMed ID: 22619113
[TBL] [Abstract][Full Text] [Related]
22. Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia.
Djuzenova CS; Blassl C; Roloff K; Kuger S; Katzer A; Niewidok N; Günther N; Polat B; Sukhorukov VL; Flentje M
Cancer Biol Ther; 2012 Apr; 13(6):425-34. PubMed ID: 22286776
[TBL] [Abstract][Full Text] [Related]
23. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
[TBL] [Abstract][Full Text] [Related]
24. Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.
Okui T; Shimo T; Fukazawa T; Mohammad Monsur Hassan N; Honami T; Ibaragi S; Takaoka M; Naomoto Y; Sasaki A
Curr Cancer Drug Targets; 2013 Mar; 13(3):289-99. PubMed ID: 23016912
[TBL] [Abstract][Full Text] [Related]
25. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients.
Gaykema SB; Schröder CP; Vitfell-Rasmussen J; Chua S; Oude Munnink TH; Brouwers AH; Bongaerts AH; Akimov M; Fernandez-Ibarra C; Lub-de Hooge MN; de Vries EG; Swanton C; Banerji U
Clin Cancer Res; 2014 Aug; 20(15):3945-54. PubMed ID: 25085789
[TBL] [Abstract][Full Text] [Related]
26. Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer.
Yeramian A; García V; Bergadà L; Domingo M; Santacana M; Valls J; Martinez-Alonso M; Carceller JA; Cussac AL; Dolcet X; Matias-Guiu X
Mol Imaging Biol; 2016 Aug; 18(4):545-56. PubMed ID: 26604096
[TBL] [Abstract][Full Text] [Related]
27. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
[TBL] [Abstract][Full Text] [Related]
28. HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Yang H; Lee MH; Park I; Jeon H; Choi J; Seo S; Kim SW; Koh GY; Park KS; Lee DH
Cancer Lett; 2017 Dec; 411():19-26. PubMed ID: 28987383
[TBL] [Abstract][Full Text] [Related]
29. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
[TBL] [Abstract][Full Text] [Related]
30. Targeting HSP90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer.
Moser C; Lang SA; Hackl C; Wagner C; Scheiffert E; Schlitt HJ; Geissler EK; Stoeltzing O
Anticancer Res; 2012 Jul; 32(7):2551-61. PubMed ID: 22753713
[TBL] [Abstract][Full Text] [Related]
31. Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α.
Stingl L; Niewidok N; Müller N; Selle M; Djuzenova CS; Flentje M
Strahlenther Onkol; 2012 Jun; 188(6):507-15. PubMed ID: 22441439
[TBL] [Abstract][Full Text] [Related]
32. Hsp90 Inhibitor; NVP-AUY922 in Combination with Doxorubicin Induces Apoptosis and Downregulates VEGF in MCF-7 Breast Cancer Cell Line.
Mohammadian M; Feizollahzadeh S; Mahmoudi R; Toofani Milani A; Rezapour-Firouzi S; Karimi Douna B
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1773-1778. PubMed ID: 32592377
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
[TBL] [Abstract][Full Text] [Related]
34. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.
Nagengast WB; de Korte MA; Oude Munnink TH; Timmer-Bosscha H; den Dunnen WF; Hollema H; de Jong JR; Jensen MR; Quadt C; Garcia-Echeverria C; van Dongen GA; Lub-de Hooge MN; Schröder CP; de Vries EG
J Nucl Med; 2010 May; 51(5):761-7. PubMed ID: 20395337
[TBL] [Abstract][Full Text] [Related]
35. HSP90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells.
Liu J; Sun W; Dong W; Wang Z; Qin Y; Zhang T; Zhang H
Biochem Biophys Res Commun; 2017 May; 487(2):313-319. PubMed ID: 28412368
[TBL] [Abstract][Full Text] [Related]
36. The Hsp70 inhibiting peptide aptamer A17 potentiates radiosensitization of tumor cells by Hsp90 inhibition.
Schilling D; Garrido C; Combs SE; Multhoff G
Cancer Lett; 2017 Apr; 390():146-152. PubMed ID: 28108313
[TBL] [Abstract][Full Text] [Related]
37. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
[TBL] [Abstract][Full Text] [Related]
38. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.
Augello G; Emma MR; Cusimano A; Azzolina A; Mongiovì S; Puleio R; Cassata G; Gulino A; Belmonte B; Gramignoli R; Strom SC; McCubrey JA; Montalto G; Cervello M
Int J Cancer; 2019 May; 144(10):2613-2624. PubMed ID: 30488605
[TBL] [Abstract][Full Text] [Related]
39. Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922.
Bergstrom M; Monazzam A; Razifar P; Ide S; Josephsson R; Langstrom B
J Nucl Med; 2008 Jul; 49(7):1204-10. PubMed ID: 18552146
[TBL] [Abstract][Full Text] [Related]
40. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer.
Ueno T; Tsukuda K; Toyooka S; Ando M; Takaoka M; Soh J; Asano H; Maki Y; Muraoka T; Tanaka N; Shien K; Furukawa M; Yamatsuji T; Kiura K; Naomoto Y; Miyoshi S
Lung Cancer; 2012 Apr; 76(1):26-31. PubMed ID: 21996088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
